Allarity Therapeutics, Inc. ((ALLR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Allarity Therapeutics, Inc. is conducting a Phase 2 study titled Phase 2, Randomized, Prospective, Open-Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti-Tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer. The study aims to determine the optimal dose of 2X-121 for treating recurrent, advanced ovarian cancer, especially in patients resistant to platinum-based chemotherapy. This research is significant as it seeks to improve treatment options for a challenging condition.
The intervention being tested is the drug 2X-121, administered in two different dosages: 600 mg and 800 mg daily. The purpose is to find the most effective and safe dose for patients with advanced ovarian cancer.
The study design is interventional, with a randomized allocation and a parallel intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused.
The study began on March 8, 2019, with the latest update submitted on August 22, 2025. These dates are crucial as they mark the study’s progression and the most recent developments in the research.
This update could influence Allarity Therapeutics’ stock performance positively by showcasing progress in their clinical pipeline, potentially boosting investor confidence. In the competitive landscape of cancer treatment, advancements in drug efficacy and safety can significantly impact market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.